INmune Bio's INKmune Shows Positive Efficacy In Multiple Cancer Cell Lines

 

• INmune Bio Inc 
  INMB+2.96%+ Free Alerts
   has announced solid tumor data in multiple cancer lines resistant to NK killing that can be overcome with the administration of INKmune.
• The Tumor Microenvironment (TME) interaction with cancer cells and immune cells can drive tumor progression and prevent many cell therapies from being effective. 
• INKmune converts the patient's normal resting NK (rNK) cells into potent memory-like NK cells that target solid tumors directly, even in the presence of immunosuppressive immunoregulatory cells and hypoxia associated with the TME.
• The company's preclinical data show that INKmune primes NK cells from patients and healthy donors to lyse NK-resistant ovarian (CaOva), prostate (CaPros), renal (RCC), and nasopharyngeal (NPC) cancer cells.
• Compared to rNK cells, which are normal NK cells from healthy donors or patients before treatment with INKmune, the INKmune-primed NK cells demonstrated an enhanced ability to kill these resistant tumor cell lines.
• The company identified more than 1,500 proteins that are upregulated in NK cells following INKmune priming and subsequent analysis compared them to NK cells primed with a cytokine cocktail of IL-12, IL-15 and IL-18. 

https://www.benzinga.com/general/biotech/22/10/29326630/inmune-bios-inkmune-shows-positive-efficacy-in-multiple-cancer-cell-lines